Cited by 3,559Angiogenesis and VEGF in CancerCancer Cells and MetastasisMathematical Biology Tumor Growth

The DOI matches its Crossref record; 110 of the 110 references it cites were found in a registry or an index.

Tumorigenesis and the angiogenic switch

Bergers, Gabriele, Benjamin, Laura E.·2003·Nature reviews. Cancer

Open this paper in CoChat — free account

Abstract

It has become evident that we cannot understand tumour growth without considering components of the stromal microenvironment, such as the vasculature. At the same time, the tumour phenotype determines the nature of the tumour vasculature. Much research is now devoted to determining the impact of angiogenesis on tumour development and progression, and the reciprocal influences of tumour products on the microvasculature. A more detailed understanding of the complex parameters that govern the interactions between the tumour and vascular compartments will help to improve anti-angiogenic strategies-- not only for cancer treatment, but also for preventing recurrence.

Integrity signals

Registry

Crossref · 10.1038/nrc1093

Cites

110 of 110 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis
Watnick, R. S., Cheng, Y.-N., Rangarajan, A., Ince, T. A., & Weinberg, R. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00030-8 · Cited by 318
Retracted
The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., de Vries-Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,704
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Tumors: Wounds That Do Not Heal
Flier, J. S., Underhill, L. H., & Dvorak, H. F. (1986) · New England Journal of Medicine · doi:10.1056/nejm198612253152606 · Cited by 4,391
Mechanisms of angiogenesis and arteriogenesis
Carmeliet, P. (2000) · Nature Medicine · doi:10.1038/74651 · Cited by 4,235
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1
Forsythe, J. A., Jiang, B.-H., Iyer, N. V., Agani, F., Leung, S. W., Koos, R. D., & Semenza, G. L. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4604 · Cited by 3,981
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Self-citation
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J. A., Maisonpierre, P. C., Compton, D. L., Boland, P., Alexander, C., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,222
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) · Nature Medicine · doi:10.1038/nm1101-1194 · Cited by 1,860
Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions
Carmeliet, P., Moons, L., Luttun, A., Vincenti, V., Compernolle, V., Mol, M. D., Wu, Y., Bono, F., Devy, L., Beck, H., et al. (2001) · Nature Medicine · doi:10.1038/87904 · Cited by 1,708
Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Clinical translation of angiogenesis inhibitors
Kerbel, R. S., & Folkman, J. (2002) · Nature reviews. Cancer · doi:10.1038/nrc905 · Cited by 1,538
VEGF and the quest for tumour angiogenesis factors
Ferrara, N. (2002) · Nature Reviews Cancer · doi:10.1038/nrc909 · Cited by 1,536
Control of Angiogenesis in Fibroblasts by p53 Regulation of Thrombospondin-1
Dameron, K. M., Volpert, O. V., Tainsky, M. A., & Bouck, N. (1994) · Science · doi:10.1126/science.7521539 · Cited by 1,437
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. K., & Hanahan, D. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17929 · Cited by 1,361
A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF
Benjamin, L. E., Hemo, I., & Keshet, E. (1998) · Development · doi:10.1242/dev.125.9.1591 · Cited by 1,273
Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal
Benjamin, L. E., Golijanin, D., Itin, A., Pode, D., & Keshet, E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5028 · Cited by 1,234
c-MYC: more than just a matter of life and death
Pelengaris, S., Khan, M., & Evan, G. I. (2002) · Nature reviews. Cancer · doi:10.1038/nrc904 · Cited by 1,192
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
Bergers, G., Song, S., Meyer-Morse, N., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317929 · Cited by 1,192
Self-citation
Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
Klement, G. L., Baruchel, S., Rak, J. W., Man, S., Clark, K., Hicklin, D. J., Böhlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,166
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.
Ravi, R. K., Mookerjee, B., Bhujwalla, Z. M., Sutter, T. R., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · PubMed Central · Cited by 1,099
HIF-1 and tumor progression: pathophysiology and therapeutics
Semenza, G. L. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02317-1 · Cited by 1,060
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong, T. A. T., Shawver, L. K., Sun, L., Tang, C., App, H., Powell, T., Kim, Y. H., Schreck, R., Wang, X., Risau, W., et al. (1999) · PubMed · Cited by 1,026
Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia
Stone, J., Itin, A., Alon, T., Pe'er, J., Gnessin, H., Chan‐Ling, T., & Keshet, E. (1995) · Journal of Neuroscience · doi:10.1523/jneurosci.15-07-04738.1995 · Cited by 1,004
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Self-citation
Abnormalities in Pericytes on Blood Vessels and Endothelial Sprouts in Tumors
Morikawa, S., Bałuk, P., Kaidoh, T., Haskell, A., Jain, R. K., & McDonald, D. M. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64920-6 · Cited by 987
Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α
Ravi, R., Mookerjee, B., Bhujwalla, Z. M., Sutter, C. H., Artemov, D., Zeng, Q., Dillehay, L. E., Madan, A., Semenza, G. L., & Bedi, A. (2000) · Genes & Development · doi:10.1101/gad.14.1.34 · Cited by 967
Rules for Making Human Tumor Cells
Hahn, W. C., & Weinberg, R. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmra021902 · Cited by 951
Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis
Coussens, L. M., Raymond, W. W., Bergers, G., Laig-Webster, M., Behrendtsen, O., Werb, Z., Caughey, G. H., & Hanahan, D. (1999) · Genes & Development · doi:10.1101/gad.13.11.1382 · Cited by 946 · cited 1×
“, which develop pancreatic-islet carcinomas, and K14-HPV16 mice, which develop squamous-cell carcinomas of the skin and cervi”
Self-citation
Mechanisms of normal and tumor-derived angiogenesis
Papetti, M., & Herman, I. M. (2002) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00389.2001 · Cited by 809
Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us
Hlatky, L. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.12.883 · Cited by 786
Pericytes in the microvasculature
Hirschi, K. K., & D'Amore, P. A. (1996) · Cardiovascular Research · doi:10.1016/s0008-6363(96)00063-6 · Cited by 763
New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF
Holash, J. A., Wiegand, S. J., & Yancopoulos, G. D. (1999) · Oncogene · doi:10.1038/sj.onc.1203035 · Cited by 752
Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., & Augustin, H. G. (2000) · PubMed · Cited by 746
Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells
Hattori, K., Dias, S., Heissig, B., Hackett, N. R., Lyden, D. C., Tateno, M., Hicklin, D. J., Zhu, Z., Witte, L., Crystal, R. G., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.9.1005 · Cited by 688
Vasculogenic Mimicry and Tumor Angiogenesis
Folberg, R., Hendrix, M. J. C., & Maniotis, A. J. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64739-6 · Cited by 682
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I
Zhou, Z., Apte, S. S., Soininen, R., Cao, R., Baaklini, G. Y., Rauser, R. W., Wang, J., Cao, Y., & Tryggvason, K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.060037197 · Cited by 666
Cyclooxygenase 2: a molecular target for cancer prevention and treatment
Subbaramaiah, K., & Dannenberg, A. J. (2003) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(02)00043-3 · Cited by 650
Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1+ stem cells from bone-marrow microenvironment
Hattori, K., Heissig, B., Wu, Y. L., Dias, S., Tejada, R., Ferris, B., Hicklin, D. J., Zhu, Z., Böhlen, P., Witte, L., et al. (2002) · Nature Medicine · doi:10.1038/nm740 · Cited by 636
Suppression of Myc-Induced Apoptosis in β Cells Exposes Multiple Oncogenic Properties of Myc and Triggers Carcinogenic Progression
Pelengaris, S., Khan, M., & Evan, G. I. (2002) · Cell · doi:10.1016/s0092-8674(02)00738-9 · Cited by 636
Advances in diagnostic imaging and overestimations of disease prevalence and the benefits of therapy
Black, W. C., & Welch, H. G. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304293281706 · Cited by 547
Issues and progress with protein kinase inhibitors for cancer treatment
Dancey, J. E., & Sausville, E. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1066 · Cited by 526
Angiostatin binds ATP synthase on the surface of human endothelial cells
Moser, T. L., Stack, M. S., Asplin, I. R., Enghild, J. J., Højrup, P., Everitt, L., Hubchak, S. C., Schnaper, H. W., & Pizzo, S. V. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.2811 · Cited by 526
Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal
Benjamin, L. E., & Keshet, E. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.16.8761 · Cited by 511
Anti-VEGF Antibody Treatment of Glioblastoma Prolongs Survival But Results in Increased Vascular Cooption
Rubenstein, J. L., Kim, J., Ozawa, T., Zhang, M., Westphal, M., Deen, D. F., & Shuman, M. A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900102 · Cited by 510
SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
Laird, A., Vajkoczy, P., Shawver, L. K., Thurnher, A., Liang, C., Mohammadi, M., Schlessinger, J., Ullrich, A., Hubbard, S. R., Blake, R. A., et al. (2000) · PubMed · Cited by 496
Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor
Rodrı́guez-Manzaneque, J. C., Lane, T. F., Ortega, M.-A., Hynes, R. O., Lawler, J., & Iruela‐Arispe, M. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.171460498 · Cited by 473
Canstatin, a Novel Matrix-derived Inhibitor of Angiogenesis and Tumor Growth
Kamphaus, G. D., Colorado, P. C., Panka, D. J., Hopfer, H., Ramchandran, R., de la Torre, A., Maeshima, Y., Mier, J. W., Sukhatme, V. P., & Kalluri, R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.2.1209 · Cited by 470
Stabilization of Vascular Endothelial Growth Factor mRNA by Hypoxia and Hypoglycemia and Coregulation with Other Ischemia-Induced Genes
Stein, I., Neeman, M., Shweiki, D., Itin, A., & Keshet, E. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.10.5363 · Cited by 460
A role for survivin in chemoresistance of endothelial cells mediated by VEGF
Tran, J., Master, Z., Yu, J., Rak, J. W., Dumont, D., & Kerbel, R. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.072586399 · Cited by 435
Activation of the HIF pathway in cancer
Maxwell, P. H. (2001) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(00)00193-3 · Cited by 430
Effect of p53 Status on Tumor Response to Antiangiogenic Therapy
Yu, J., Rak, J. W., Coomber, B. L., Hicklin, D. J., & Kerbel, R. S. (2002) · Science · doi:10.1126/science.1068327 · Cited by 428
Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors.
Papapetropoulos, A., García‐Cardeña, G., Dengler, T. J., Maisonpierre, P. C., Yancopoulos, G. D., & Sessa, W. C. (1999) · PubMed · Cited by 418
Tumor Angiogenesis: A Quantitative Method for Histologic Grading 2
Brem, S. S., Cotran, R. S., & Folkman, J. (1972) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/48.2.347 · Cited by 415
Heterogeneity of the Angiogenic Response Induced in Different Normal Adult Tissues by Vascular Permeability Factor/Vascular Endothelial Growth Factor
Pettersson, A. F., Nagy, J. A., Brown, L. F., Sundberg, C., Morgan, E. S., Jungles, S., Carter, R., Krieger, J. E., Manseau, E. J., Harvey, V. S., et al. (2000) · Laboratory Investigation · doi:10.1038/labinvest.3780013 · Cited by 412
Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression.
Mukhopadhyay, D., Tsiokas, L., & Sukhatme, V. P. (1995) · PubMed · Cited by 403
VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic β cell carcinogenesis
Inoue, M., Hager, J. H., Ferrara, N., Gerber, H., & Hanahan, D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00031-4 · Cited by 380
Angiomotin
Troyanovsky, B., Levchenko, T., Månsson, G., Matvijenko, O., & Holmgren, L. (2001) · The Journal of Cell Biology · doi:10.1083/jcb.152.6.1247 · Cited by 378
Inhibition of Cyclooxygenase-2 Gene Expression by p53
Subbaramaiah, K., Altorki, N. K., Chung, W. J., MESTRE, J. R., Sampat, A., & Dannenberg, A. J. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.16.10911 · Cited by 355
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis.
Weinstat‐Saslow, D., Zabrenetzky, V. S., VanHoutte, K., Frazier, W. A., Roberts, D. D., & Steeg, P. S. (1994) · PubMed · Cited by 348
Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo
Brantley, D. M., Cheng, N., Thompson, E. J., Lin, Q. F., Brekken, R. A., Thorpe, P. E., Muraoka, R. S., Cerretti, D. P., Pozzi, A., Jackson, D., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205679 · Cited by 314
A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis
Nishimori, H., Shiratsuchi, T., Urano, T., Kimura, Y., Kiyono, K., Tatsumi, K., Yoshida, S., Ono, M., Kuwano, M., Nakamura, Y., et al. (1997) · Oncogene · doi:10.1038/sj.onc.1201542 · Cited by 293
Transcriptional Activation by p53 of the Human Type IV Collagenase (Gelatinase A or Matrix Metalloproteinase 2) Promoter
Bian, J., & Sun, Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.11.6330 · Cited by 274
Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis.
Cheng, N., Brantley, D. M., Liu, H., Lin, Q., Enriquez, M., Gale, N., Yancopoulos, G. D., Cerretti, D. P., Daniel, T. O., & Chen, J. (2002) · PubMed · Cited by 252
Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2
Vajkoczy, P., Farhadi, M. R., Gaumann, A. K. A., Heidenreich, R., Erber, R., Wunder, A., Tonn, J. C., Menger, M. D., & Breier, G. (2002) · Journal of Clinical Investigation · doi:10.1172/jci14105 · Cited by 247
Lysophosphatidic Acid Induction of Vascular Endothelial Growth Factor Expression in Human Ovarian Cancer Cells
Hu, Y., Tee, M. K., Goetzl, E. J., Auersperg, N., Mills, G. B., Ferrara, N., & Jaffe, R. B. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.10.762 · Cited by 246
Vascular endothelial growth factor and vascular adjustments to perturbations in oxygen homeostasis
Dor, Y., Porat, R. M., & Keshet, E. (2001) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.2001.280.6.c1367 · Cited by 244
Cyclooxygenase-2 and prostate carcinogenesis
Hussain, T., Gupta, S., & Mukhtar, H. (2003) · Cancer Letters · doi:10.1016/s0304-3835(02)00524-4 · Cited by 240
Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression.
Zhang, L., Yu, D., Hu, M., Xiong, S., Lang, A., Ellis, L. M., & Pollock, R. E. (2000) · PubMed · Cited by 230
Identification of the Anti-angiogenic Site within Vascular Basement Membrane-derived Tumstatin
Maeshima, Y., Manfredi, M. G., Reimer, C., Holthaus, K. A., Hopfer, H., Chandamuri, B. R., Kharbanda, S. M., & Kalluri, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007764200 · Cited by 229
Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines
Zabrenetzky, V. S., Harris, C. C., Steeg, P. S., & Roberts, D. D. (1994) · International Journal of Cancer · doi:10.1002/ijc.2910590209 · Cited by 219
Placental growth factor is a survival factor for tumor endothelial cells and macrophages.
Adini, A., Kornaga, T., Firoozbakht, F., & Benjamin, L. E. (2002) · PubMed · Cited by 212
Cyclooxygenase-2: a therapeutic target in angiogenesis
Iñiguez, M. A., Rodrı́guez, A., Volpert, O. V., Fresno, M., & Redondo, J. M. (2003) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)00011-4 · Cited by 206
Reactivation of a silenced H19 gene in human rhabdomyosarcoma by demethylation of DNA but not by histone hyperacetylation
Lynch, C. A., Tycko, B., Bestor, T. H., & Walsh, C. P. (2002) · Molecular Cancer · doi:10.1186/1476-4598-1-2 · Cited by 202
Central role of p53 on regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in mammary carcinoma.
Pal, S., Datta, K., & Mukhopadhyay, D. (2001) · PubMed · Cited by 196
Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis.
Elson, D. A., Riley, R. R., Lacey, A., Thórdarson, G., Talamantes, F. J., & Arbeit, J. M. (2000) · PubMed · Cited by 187
Vasculogenic Mimicry: How Convincing, How Novel, and How Significant?
McDonald, D. M., Munn, L. L., & Jain, R. K. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64740-2 · Cited by 187
Response of tumour cells to hypoxia: role of p53 and NFkB.
Royds, J. A., Dower, S., Qwarnström, E. E., & Lewis, C. E. (1998) · Molecular Pathology · doi:10.1136/mp.51.2.55 · Cited by 182
Efficient mobilization and recruitment of marrow-derived endothelial and hematopoietic stem cells by adenoviral vectors expressing angiogenic factors
Rafii, S., Heissig, B., & Hattori, K. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301723 · Cited by 175
Receptor tyrosine kinase EphA2 is regulated by p53-family proteins and induces apoptosis
Dohn, M. R., Jiang, J., & Chen, X. (2001) · Oncogene · doi:10.1038/sj.onc.1204816 · Cited by 147
How aneuploidy may cause cancer and genetic instability.
DUESBERG, P. H., Rasnick, D., Li, R., Winters, L. N., Rausch, C., & Hehlmann, R. (1999) · PubMed · Cited by 135
The antiangiogenic agent TNP-470 requires p53 and p21 CIP/WAF for endothelial cell growth arrest
Yeh, J.-R. J., Mohan, R., & Crews, C. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.23.12782 · Cited by 120
Thrombospondin-1 Gene Expression Affects Survival and Tumor Spectrum of p53-Deficient Mice
Lawler, J., Miao, W., Duquette, M. A., Bouck, N., Bronson, R. T., & Hynes, R. O. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63042-8 · Cited by 117
Angiostatin: an endogenous inhibitor of angiogenesis and of tumor growth.
OʼReilly, M. (1997) · PubMed · Cited by 115
Opposing effects of hypoxia on expression of the angiogenic inhibitor thrombospondin 1 and the angiogenic inducer vascular endothelial growth factor.
Laderoute, K. R., Alarcon, R. M., Brody, M. D., Calaoagan, J. M., Chen, E. Y., Knapp, A. M., Yun, Z., Denko, N. C., & Giaccia, A. J. (2000) · PubMed · Cited by 107
In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effectsPreprint
Filleur, S., Volpert, O. V., Degeorges, A., Voland, C., Reiher, F., Clézardin, P., Bouck, N., & Cabon, F. (2001) · Genes & Development · doi:10.1101/gad.193501 · Cited by 103
The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression
Volpert, O. V., Stellmach, V., & Bouck, N. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00666034 · Cited by 102
The Significance of Atypia and Histologic Malignancy in Pilocytic Astrocytoma of the Cerebellum: A Clinicopathologic and Flow Cytometric Study
Tomlinson, F. H., Scheithauer, B. W., Hayostek, C. J., Parisi, J. E., Meyer, F. B., Shaw, E. G., Weiland, T. L., Katzmann, J. A., & Jack, C. R. (1994) · Journal of Child Neurology · doi:10.1177/088307389400900317 · Cited by 102
Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis
Bergers, G., Hanahan, D., & Coussens, L. M. (1998) · The International Journal of Developmental Biology · doi:10.1387/ijdb.9853830 · Cited by 89
Thrombospondin‐1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia
Kwak, C. H., Jin, R., Lee, C. H., Park, M. S., & Lee, S. E. (2002) · British Journal of Urology · doi:10.1046/j.1464-4096.2001.01417.x · Cited by 75
Aerosol delivery of PEI–p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis
Gautam, A. K., Densmore, C. L., Melton, S., Golunski, E., & Waldrep, J. C. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700405 · Cited by 71
Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12.
Gee, M. S., Koch, C. J., Evans, S. M., Jenkins, W. T., Pletcher, C. H., Moore, J. S., Koblish, H. K., Lee, J. J., Lord, E. M., Trinchieri, G., et al. (1999) · PubMed · Cited by 71
Antiangiogenic treatment with linomide as chemoprevention for prostate, seminal vesicle, and breast carcinogenesis in rodents.
Joseph, I. B. J., Vukanovic, J., & Isaacs, J. T. (1996) · PubMed · Cited by 56
p53 induces angiogenesis-restricted dormancy in a mouse fibrosarcoma
Holmgren, L., Jackson, G., & Arbiser, J. L. (1998) · Oncogene · doi:10.1038/sj.onc.1201993 · Cited by 54
Chemoprevention of Prostate Cancer: Current Status and Future Directions
Lieberman, R. (2002) · Cancer and Metastasis Reviews · doi:10.1023/a:1021267128567 · Cited by 47
High cyclooxygenase-2 expression in cervical adenocarcinomas
Chen, Y., Wang, L.-S., Wang, P., Lai, C.-R. U., Yen, M.-S., Ng, H., & Yuan, C. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(02)00066-5 · Cited by 46
p53 does not repress hypoxia-induced transcription of the vascular endothelial growth factor gene.
Agani, F. H., Kirsch, D. G., Friedman, S. L., Kastan, M. B., & Semenza, G. L. (1997) · PubMed · Cited by 37
Expression of oestrogen receptor and oestrogen-inducible genes ps2 and erd5 in large bowel mucosa and cancer
Singh, S., Poulsom, R., Hanby, A. M., Rogers, L. A., Wright, N. A., Sheppard, M. C., & Langman, M. J. S. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199802)184:2 · Cited by 33
Hypoxia upregulates Bcl‐2 expression and suppresses interferon‐γ induced antiangiogenic activity in human tumor derived endothelial cells
Wang, J. H., Wu, Q. D., Bouchier-Hayes, D., & Redmond, H. P. (2002) · Cancer · doi:10.1002/cncr.10520 · Cited by 33
Combining Antiangiogenic Agents with Metronomic Chemotherapy Enhances Efficacy against Late-stage Pancreatic Islet Carcinomas in MicePreprint
Bergers, G., & Hanahan, D. (2002) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2002.67.293 · Cited by 29
Prediction of in vivo synergistic activity of antiangiogenic compounds by gene expression profiling.
Cline, E. I., Bicciato, S., DiBello, C., & Lingen, M. W. (2002) · PubMed · Cited by 28
Human Metalloproteinase‐1 (Collagenase‐1) Is a Tumor Suppressor Protein p53 Target Gene
Sun, Y., Sun, Y., Wenger, L., Rutter, J. L., Brinckerhoff, C., & Cheung, H. S. (1999) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1999.tb07749.x · Cited by 15
Multiple drug resistance phenotype of human endothelial cells induced by vascular endothelial growth factor 165.
Zhang, X., Zhu, X., Gao, J., Qian, C., Kuang, Z.-J., Liu, Z., & Zeng, Y. (2001) · PubMed · Cited by 13
Renal cell carcinoma may adapt to and overcome anti‐angiogenic intervention with thalidomide
Douglas, M. L., Reid, J. L., Hii, S.-I., Jonsson, J. R., & Nicol, D. L. (2002) · British Journal of Urology · doi:10.1046/j.1464-410x.2002.02666.x · Cited by 10
Anti-angiogenic drug AGM1470 suppresses smooth muscle cell migration induced by endothelial PDGF
Shigematsu, K., Yasuhara, H., Shigematsu, H., & Muto, T. (1997) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/s1078-5884(97)80241-9 · Cited by 5

Flagged first, then by citations

Research works printed but not linked: 2

Folkman, J. in Cancer Medicine (Holland, M.D. et al.) 2546 (BC Decker, Hamilton, Ontario, 2000).
Sternlicht, M. D. et al. Matrix proteinases as emerging targets in anticancer therapy: status and prospects. ETT 4, 609–633 (2000).

Sorted by citations

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Oxidative stress, inflammation, and cancer: How are they linked?
Reuter, S., Gupta, S. C., Chaturvedi, M. M., & Aggarwal, B. B. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.09.006 · Cited by 5,441
Vascular Endothelial Growth Factor: Basic Science and Clinical Progress
Ferrara, N. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0027 · Cited by 3,788
To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery
Danhier, F., Féron, O., & Véronique Préat, A. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,891
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625

See all 3,559

Authors: Bergers, G., & Benjamin, L. E.
Affiliations: University of California, San Francisco (US)
Beth Israel Deaconess Medical Center (US)
Corresponding author: Bergers, Gabriele
ORCID: Bergers, Gabriele
Venue: Nature reviews. Cancer
Publisher: Springer Science and Business Media LLC
Published: 2003-06
Volume: 3
Issue: 6
Pages: 401-410
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc1093
OpenAlex: W2804842145
Cited by: 3,559
References: 110
Citations by year: 2026: 53 · 2025: 79 · 2024: 123 · 2023: 122 · 2022: 142 · 2021: 160 · 2020: 149 · 2019: 159 · 2018: 162 · 2017: 176 · 2016: 148 · 2015: 176 · 2014: 232 · 2013: 223 · 2012: 198
FWCI: 9.49
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
Keywords: carcinogenesis, angiogenic switch, tumor angiogenesis, tumor vasculature, tumor microenvironment, tumor-stroma interactions, tumor progression, anti-angiogenic therapy, tumor recurrence
MeSH terms: Animals, Humans, Neoplasms, Neovascularization, Pathologic, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tumorigenesis and the angiogenic switch

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks